A breakthrough in infant care, so you can help babies thrive
Get Evivo for your patients today
Parents want your recommendations
Whether you are a pediatrician, lactation consultant, OB, or midwife, when you recommend Evivo, you’re helping baby meet a key milestone that safeguards health – establishing a healthy gut microbiome.
Evivo Advocate Program
Offer parents the convenience of buying Evivo directly from you. Advocates receive our full support through on-site training, tool kits, and priority customer service.
For Health Systems
Evivo improves gut health for all newborns, including our most fragile NICU patients like those born preterm and other high-risk infants. Raise the standard of care at your place of practice with Evivo.
Resources
We can explain the science behind Evivo because we made the discoveries – explore our peer-reviewed articles, white papers, podcasts, and more.
Evivo Infant Probiotics
Our research to understand mysteries within breast milk led us to discover the power of its synergy with B. infantis EVC001. The single strain that matters for infants, and only found in Evivo.
Evivo Powder
A daily powder intended for babies fed any amount of breast milk to help establish a protective gut microbiome and support healthy immune function.
Evivo with MCT Oil
Ready-to-use, single-serve liquid made specifically for NICU and Labor and Delivery use, proven to help stabilize and protect the infant gut against potential hospital acquired pathogens.
Schedule a presentation with our team of doctors & nurses
Jennifer Bragg, MD
Neonatologist
VP, Clinical Implementation
Payal Adhikari, MD
Pediatrician
Director, Clinical Implementation
Albert Antonio, DO
Neonatologist
Director, Clinical Implementation
Erin Qualter, MD
Neonatologist
Director, Clinical Implementation
Carrie McGuckin, BSN, RNC-NIC
NICU Nurse
Associate Director, Corporate Excellence
Connect with us
Call us at (844) 463-8486 for customer service, support, and to learn more about our products.
Completed Clinical Studies
Findings that support the use of B. infantis EVC001, the single strain in Evivo, to better health.
Study design
A single-blind randomized clinical trial during the rehabilitation of less than 6 month old infants with severe acute malnutrition in Bangladesh. Four weeks after the supplementation period, signs of improved ponderal growth (e.g. rate of weight gain and WAZ scores were significantly higher in infants who had been supplemented with the probiotic (B. infantis EVC001) for 28 days.
| Finding | Publication |
|---|---|
| B. infantis EVC001 improves growth | Nuzhat, Sharika, et al. 2023 Scientific Reports |
Study design
Parallel two arm randomized open label study to determine the effects of feeding B. infantis EVC001 for the first 21 days of life in healthy term breastfed infants delivered via C-section or vaginal delivery on gut bacteria composition compared with matched-control term infants receiving standard care.
| Findings | Publication |
|---|---|
| B. infantis EVC001 is safe and tolerable | Smilowitz, J. et al. 2017 BMC Pediatrics |
| B. infantis EVC001 colonizes breastfed infants and persists beyond supplementation period | Frese et al. 2017 mSphere |
| Infants fed B. infantis EVC001 had significantly less virulence factors in their microbiomes compared to control | Casaburi, G. & Frese 2018 Human Microbiome Journal |
| Infants fed B. infantis EVC001 had significantly less mucin glycans in the stool suggesting improved mucin layer integrity | Karav 2018 FEBS Open Bio 8, |
| Infants fed B. infantis EVC001 resulted in significantly less enteric inflammation | Henrick et al. 2019 Pediatric Research |
| Infants fed B. infantis EVC001 had significantly less antibiotic resistant genes than breastfed infants lacking B. infantis | Casaburi et al. 2019 Antibiotic Resistance & Infection Control |
| Infants fed B. infantis EVC001 have less inflammation and immune markers associated with allergy and autoimmune diseases | Henrick et al. 2021 Cell |
Study design:
A single-blind randomized clinical trial during the rehabilitation of less than 6 month old infants with severe acute malnutrition in Bangladesh. Four weeks after the supplementation period, signs of improved ponderal growth (e.g. rate of weight gain and WAZ scores were significantly higher in infants who had been supplemented with the probiotic (B. infantis EVC001) for 28 days.
| Finding | Publication |
|---|---|
| B. infantis EVC001 improves growth | Nuzhat, Sharika, et al. 2023 Scientific Reports |
Study design
In this single-center observational cohort study demonstrates that supplementing an HMO-catabolizing Bifidobacterium probiotic (B. infantis EVC001) results in increased microbial metabolism of milk oligosaccharides and reduced intestinal inflammation relative to a noncatabolizing Lactobacillus probiotic in human milk-fed preterm infants.
| Finding | Publication |
|---|---|
| B. infantis EVC001 was shown to improve microbial metabolism of milk oligosaccharides and decrease intestinal inflammation in human milk-fed preterm infants. | Larke, Jules A., et al. Journal of Pediatric Gastroenterology and Nutrition |
Study design
A prospective, open-label study design was used to evaluate the tolerability of B. infantis EVC001 and its effects on the fecal microbiota in preterm infants at Orlando Health Winnie Palmer Hospital for Women and Babies (level III NICU).
| Finding | Publication |
|---|---|
| B. infantis EVC001 is safe, well tolerated by preterm infants (<33 weeks gestational age or <1,500 g birth weight) | Bajorek et al. 2022 Frontiers in Pediatrics |
Study design
Prospective longitudinal analysis of two cohorts of preterm infants at 2 southern California Kaiser hospitals (Level II and Level III NICUs).
| Finding | Publication |
|---|---|
| Preterm infants fed B. infantis EVC001 had significantly less antibiotic resistant genes in their microbiome, significantly fewer incidences of diaper rash and significantly lower enteric inflammation. | Nguyen, M. et al. Frontiers in Pediatrics |
Study design:
Nonconcurrent retrospective analysis of 2 cohorts of very low birth weight (VLBW) infants at Oregon Health State University Doernbecher Children’s Hospital (Level IV NICU).
| Finding | Publication |
|---|---|
| Administration of B. infantis EVC001 was associated with 73% reductions in the risk of Necrotizing Enterocolitis (NEC) and zero NEC-related mortality in all low-birth-weight infants | Tobias et al. 2022 Journal of Pediatrics |